Gout Flare Treatment in CKD

For a first monoarthritis, atypical site or pattern, fever, marked systemic illness, immunosuppression, or concern for infection, perform arthrocentesis before injecting glucocorticoid. Send synovial fluid for crystal examination and bacterial culture; a prior history of gout does not remove the need to assess septic arthritis. ASCO+1ASCOManagement of Immune-Related Adverse Events in Patients ...ccjmHow is it different in patients with chronic kidney disease?

Once gout is the working diagnosis, initiate anti-inflammatory treatment early after symptom onset; earlier therapy is associated with more rapid flare control. Use local ice as an adjunct, and give patients with recurrent, well-characterized flares a prearranged early-treatment plan. Kidney International+1Kidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation and ...PubMedManagement of Gout and Hyperuricemia in CKD - PMC

Document CKD stage or current kidney function, heart-failure status, peptic-ulcer history, diabetes control, current colchicine exposure, and concomitant medications before selecting therapy. CKD frequently coexists with contraindications to NSAIDs and can limit colchicine use through reduced clearance and drug interactions. Nature+2NatureManagement of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews Rheumatologynice org uk[PDF] Gout: diagnosis and management - NICEPubMedManagement of Gout and Hyperuricemia in CKD - PMC

NSAIDs are generally a poor default in CKD because they are associated with interstitial nephritis, analgesic nephropathy, hypertension, and higher kidney-failure risk with indiscriminate chronic use. In acute gout, use only if renal and hemodynamic risk is acceptable and under careful supervision; CKD-focused reviews characterize NSAIDs as relatively contraindicated or contraindicated for flare treatment and prophylaxis. Kidney International+2Kidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation and ...PubMedManagement of Gout and Hyperuricemia in CKD - PMCccjmHow is it different in patients with chronic kidney disease?

For monoarticular or oligoarticular disease, aspiration followed by intra-articular glucocorticoid minimizes systemic exposure. In a retrospective CKD cohort with single-joint gout, triamcinolone 20-40 mg intra-articularly and oral prednisone 0.1-0.3 mg/kg/day produced similar relief and time to resolution; this was not a randomized superiority comparison. BMJ+1BMJSAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of Acute Gout Flare in Patients with Chronic Renal Failure | Annals of the Rheumatic DiseasesScienceDirectSAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of Acute Gout Flare in Patients with Chronic Renal Failure

For polyarticular disease or when injection is impractical, systemic glucocorticoids are a mainstay in CKD. In patients with concomitant congestive heart failure, consider the tradeoff between systemic glucocorticoid exposure and volume risk; a CKD review identifies dexamethasone as an alternative with lower mineralocorticoid potency when systemic treatment is needed. PubMed+1PubMedManagement of Gout and Hyperuricemia in CKD - PMCccjmHow is it different in patients with chronic kidney disease?

Start or optimize urate-lowering therapy for tophaceous gout, radiographic gout damage, or frequent flares. After a first flare, conditionally consider urate lowering when CKD stage 3 or higher, serum urate above 9 mg/dL, or urolithiasis is present; otherwise, initiation after an uncomplicated first flare is conditionally discouraged. rheumatology+1rheumatologyPress Release: Gout Management Guideline | American College of RheumatologyPubMed2020 American College of Rheumatology Guideline for the ... - PMC

Use allopurinol as preferred first-line urate-lowering therapy, including in moderate-to-severe CKD. Start at 100 mg/day or lower in CKD, then titrate using serial serum urate measurements to maintain serum urate below 6 mg/dL rather than accepting a fixed dose. Evidence supports dose escalation, including doses above 300 mg/day, in many patients with stage 3 CKD when titrated to target. rheumatology+2rheumatologyPress Release: Gout Management Guideline | American College of RheumatologyPubMedImplications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alertPubMed2020 American College of Rheumatology Guideline for the ... - PMC

Before allopurinol in patients of Han Chinese, Korean, Thai, or African American ancestry, obtain HLA-B*58:01 testing; ACR conditionally recommends against routine testing in other racial or ethnic groups. This result changes agent selection and counseling because the testing strategy is intended to reduce allopurinol hypersensitivity risk in higher-prevalence populations. rheumatologyrheumatologyPress Release: Gout Management Guideline | American College of Rheumatology

Reassess the flare if pain, swelling, or function fails to improve after the selected intervention. Reconsider septic arthritis, calcium pyrophosphate crystal arthritis, inadequate local coverage in polyarticular disease, or an alternative inflammatory arthritis; crystal arthropathies and septic arthritis remain key differentials for inflammatory monoarthritis. ASCO+1ASCOManagement of Immune-Related Adverse Events in Patients ...ccjmHow is it different in patients with chronic kidney disease?

For colchicine exposure in CKD, actively query muscle pain and weakness and review blood counts, creatine kinase, and aminotransferases when toxicity is suspected. This monitoring is particularly important because CKD reduces colchicine clearance and therapeutic-dose use may be constrained in patients with overlapping heart failure or advanced kidney disease. Nature+2NatureManagement of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews RheumatologyScienceDirectAnakinra Could Be a Glucocorticoid-sparing Alternative for Colchicine-intolerant/refractory Gout Flare in Acute Heart Failure; Case Series - ScienceDirectccjmHow is it different in patients with chronic kidney disease?

At each urate-lowering follow-up, obtain serum urate and adjust dose toward below 6 mg/dL. Failure to reach target should prompt assessment of adherence, dose escalation capacity, treatment tolerance, and the need to switch from allopurinol to febuxostat rather than accepting persistent hyperuricemia and recurrent inflammation. PubMed+2PubMedComparative Effectiveness of Allopurinol and Febuxostat in Gout Management - PMCPubMedImplications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alertPubMed2020 American College of Rheumatology Guideline for the ... - PMC